BCL2 Binding Component 3 (BBC3) (N-Term) antibody

Details for Product No. ABIN151174
Request Want additional data for this product?

The Independent Validation Initiative strives to provide you with high quality data. Find out more

Antigen
Synonyms JFY-1, JFY1, PUMA, PUMA/JFY1, Puma, BBC3
Epitope
N-Term
(40), (19), (12), (6), (3), (2), (2), (2), (1), (1), (1), (1), (1)
Reactivity
Human
(154), (54), (52), (12), (12), (2)
Host
Rabbit
(119), (41), (3)
Clonality
Polyclonal
Conjugate
Un-conjugated
(2), (2), (1), (1), (1), (1), (1), (1), (1), (1), (1), (1), (1), (1), (1), (1)
Application
Immunohistochemistry (Paraffin-embedded Sections) (IHC (p)), Western Blotting (WB)
(148), (61), (23), (20), (19), (17), (10), (5), (4), (1), (1)
Pubmed 4 references available
Catalog no. ABIN151174
Quantity 50 µg
Price
Contact our Customer Service for availability and price in your country.
Shipping to United States (Change)
Add to Basket

Order hotline:

  • +1 404 474 4654
  • +1 888 205 9894 (TF)
Immunogen Synthetic peptide: ARARQEGSSPEPVEG, corresponding to amino acids 2-16 ofHuman PUMA.
Specificity Species Reactivity: Cross-reacts with Human. Expected to cross-react with Mouse (100% identical),Rat(100% identical) due to sequence homology. Not yet tested in other species.
Cross-Reactivity Human, Mouse (Murine), Rat (Rattus)
Purification Affinity Purified
Alternative Name PUMA
Background Apoptosis is related to many diseases and development. The p53 tumor-suppressorprotein induces apoptosis through transcriptional activation of several genes. A novelp53 inducible pro-apoptotic gene was identified recently and designated PUMA (for p53upregulated modulator of apoptosis) and bbc3 (for Bcl-2 binding component 3) in humanand mouse (1-3). PUMA/bbc3 is one of the pro-apoptotic Bcl-2 family membersincluding Bax and Noxa, which are also transcriptional targets of p53. The PUMA geneencodes two BH3 domain-containing proteins termed PUMA-a and PUMA-b (1). PUMAproteins bind Bcl-2, localize to the mitochondria, and induce cytochrome c release andapoptosis in response to p53. PUMA may be a direct mediator of p53-inducedapoptosis. Alternate Names: anti-p53 Upregulated Modulator of Apoptosis antibody, anti-Bcl-2 binding component 3antibody, anti-JFY-1 antibody.
Gene ID 27113
Research Area Apoptosis/Necrosis
Application Notes Positive Controls: K562 lysate
Restrictions For Research Use only
Buffer PBS with 0.02% sodium azide
Preservative Sodium azide
Storage -20 °C
Supplier Images
anti-BCL2 Binding Component 3 (BBC3) (N-Term) antibody PUMA ? staining of human breast carcinoma with anti-PUMA (NT) at 10 ?g/ml. Formalin fixed paraffin processed tissue.
General Yu, Zhang, Hwang et al.: "PUMA induces the rapid apoptosis of colorectal cancer cells." in: Molecular cell, Vol. 7, Issue 3, pp. 673-82, 2001 (PubMed).

Nakano, Vousden: "PUMA, a novel proapoptotic gene, is induced by p53." in: Molecular cell, Vol. 7, Issue 3, pp. 683-94, 2001 (PubMed).

Han, Flemington, Houghton et al.: "Expression of bbc3, a pro-apoptotic BH3-only gene, is regulated by diverse cell death and survival signals." in: Proceedings of the National Academy of Sciences of the United States of America, Vol. 98, Issue 20, pp. 11318-23, 2001 (PubMed).

Stankovic, Hubank, Cronin et al.: "Microarray analysis reveals that TP53- and ATM-mutant B-CLLs share a defect in activating proapoptotic responses after DNA damage but are distinguished by major differences in activating prosurvival responses." in: Blood, Vol. 103, Issue 1, pp. 291-300, 2003 (PubMed).

Hosts (119), (41), (3)
Reactivities (154), (54), (52), (12), (12), (2)
Applications (148), (61), (23), (20), (19), (17), (10), (5), (4), (1), (1)
Conjugates (2), (2), (1), (1), (1), (1), (1), (1), (1), (1), (1), (1), (1), (1), (1), (1)
Epitopes (40), (19), (12), (6), (3), (2), (2), (2), (1), (1), (1), (1), (1)
Request Want additional data for this product?

The Independent Validation Initiative strives to provide you with high quality data. Find out more

Add to Basket

Order hotline:

  • +1 404 474 4654
  • +1 888 205 9894 (TF)
Validation Images
back to top